Patient characteristics at study inclusion
| Patient characteristics . | ||
|---|---|---|
| . | n (% missing value) . | Median (IQR) / n (%) . |
| Age | 1708 (0%) | 61 (52-68) |
| Female | 1708 (0%) | 794 (46%) |
| Tumor type | 1708 (0%) | |
| Brain | — | 234 (14%) |
| Lymphoma | — | 221 (13%) |
| Others | — | 132 (8%) |
| Breast | — | 267 (16%) |
| Lung | — | 321 (19%) |
| Gastroesophageal | — | 53 (3%) |
| Colorectal | — | 159 (9%) |
| Pancreas | — | 117 (7%) |
| Renal | — | 37 (2%) |
| Prostate | — | 125 (7%) |
| Myeloma | — | 42 (2%) |
| Risk groups | 1708 (0%) | |
| Very high risk | — | 327 (19%) |
| Intermediate risk | — | 986 (58%) |
| Low risk | — | 395 (23%) |
| Metastatic disease (solid tumor patients) | 1445 (15%) | 548 (32%) |
| Median follow-up period (month) | 1708 (0%) | 24 (10-24) |
| Blood type (ABO) | 1708 (0%) | |
| O | — | 653 (38%) |
| A | — | 682 (40%) |
| B | — | 262 (15%) |
| AB | — | 111 (7%) |
| Biomarker levels at study inclusion | — | |
| FVIII (% activity) | 1618 (5%) | 186 (143-239) |
| vWF-Ag levels (IU/dL) | 626 (63%) | 177 (119-269) |
| Outcomes within 2-y follow-up | 1708 (0%) | |
| VTE | — | 151 (8.8%) |
| Death | — | 649 (38%) |
| Patient characteristics . | ||
|---|---|---|
| . | n (% missing value) . | Median (IQR) / n (%) . |
| Age | 1708 (0%) | 61 (52-68) |
| Female | 1708 (0%) | 794 (46%) |
| Tumor type | 1708 (0%) | |
| Brain | — | 234 (14%) |
| Lymphoma | — | 221 (13%) |
| Others | — | 132 (8%) |
| Breast | — | 267 (16%) |
| Lung | — | 321 (19%) |
| Gastroesophageal | — | 53 (3%) |
| Colorectal | — | 159 (9%) |
| Pancreas | — | 117 (7%) |
| Renal | — | 37 (2%) |
| Prostate | — | 125 (7%) |
| Myeloma | — | 42 (2%) |
| Risk groups | 1708 (0%) | |
| Very high risk | — | 327 (19%) |
| Intermediate risk | — | 986 (58%) |
| Low risk | — | 395 (23%) |
| Metastatic disease (solid tumor patients) | 1445 (15%) | 548 (32%) |
| Median follow-up period (month) | 1708 (0%) | 24 (10-24) |
| Blood type (ABO) | 1708 (0%) | |
| O | — | 653 (38%) |
| A | — | 682 (40%) |
| B | — | 262 (15%) |
| AB | — | 111 (7%) |
| Biomarker levels at study inclusion | — | |
| FVIII (% activity) | 1618 (5%) | 186 (143-239) |
| vWF-Ag levels (IU/dL) | 626 (63%) | 177 (119-269) |
| Outcomes within 2-y follow-up | 1708 (0%) | |
| VTE | — | 151 (8.8%) |
| Death | — | 649 (38%) |
Blood type was available in 1708, FVIII activity in 1618, and vWF antigen in 626 patients.